New hope for brain metastases: Dual-Drug attack on HER2 breast cancer
NCT ID NCT07152782
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly assigned to one of the two treatment groups. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (a targeted antibody-drug conjugate) and neratinib (a targeted pill that blocks HER family signals)
What this could lead to
If successful, this could provide a new, more effective treatment option for people with HER2-positive breast cancer that has spread to the brain, potentially improving how long the cancer stays under control.
What could go wrong
This is a Phase II trial, so it is still early. The combination may not work better than the standard drug alone, or side effects could be more severe. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••